Abstract
Background: Domino transplant occurs when a recipient explanted graft is used for a second recipient.
Introduction: The first experience came from thoracic surgery by the observation that many patients during heart-lung transplantation actually showed a functional heart that could be employed in other subjects with a good result.
Results: This concept was then extended to the field of liver transplantation. At present, some patients transplanted for an inborn metabolic disease may be considered as excellent domino liver donors.
Conclusion: The results, limitations, clinical challenges and the donor and recipient features of domino liver transplantation are discussed in this manuscript.
Keywords: Amyloidosis transthyretin, domino, human, inborn disease, liver, transplantation.
Graphical Abstract
[1]
Klepetko W, Wollenek G, Laczkovics A, Laufer G, Wolner E. Domino transplantation of heart-lung and heart: An approach to overcome the scarcity of donor organs. J Heart Lung Transplant 1991; 10: 129-31.
[2]
Moini M, Mistry P, Schilsky ML. Liver transplantation for inherited metabolic disorders of the liver. Curr Opin Organ Transplant 2010; 15: 269-76.
[3]
Hemming AW, Cattral MS, Greig PD, et al. Domino liver transplantation for familial amyloid polyneuropathy: optimal use of a scarce resource. Transplant Proc 1999; 31: 515.
[4]
Furtado AJL. Domino liver transplantation using livers from patients with familial amyloidotic polyneuropathy. Curr Opin Organ Transplant 2000; 5: 69-73.
[5]
Familial Amyloidotic Polyneuropathy World Transplant registry and Domino Liver Transplant Registry. Available from
http: //www.fapwtr.org/.
[6]
Geyer ED, Burrier C, Tumin D, et al. Outcomes of domino liver transplantation compared to deceased donor liver transplantation: A propensity-matching approach. Transpl Int 2018; 31: 1200-6.
[7]
Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005; 62: 1057-62.
[8]
Sousa A, Coelho T, Barros J, Sequeiros J. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Póvoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet 1995; 60: 512-21.
[9]
Ericzon B-G, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: After 20 years still the best therapeutic alternative? Transplantation 2015; 99: 1847-54.
[10]
Coelho LF, Martins da Silva A, Waddington CM, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial. Neurology 2012; 79: 785-92.
[11]
Parman Y, Adams D, Obici L, et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: Where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol 2016; 29(Suppl. 1): S3-S13.
[12]
Berk JL, Suhr OB, Sekijima Y, et al. The diflunisal trial: Study accrual and drug tolerance. Amyloid 2012; 19(Suppl. 1): 37-8.
[13]
Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21.
[14]
Hellman U, Alarcon F, Lundgren H-E, et al. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008; 15: 181-6.
[15]
Marín-Gómez LM, Gómez-Bravo MÁ, Barrera-Pulido L, et al. Outcomes of domino liver transplantation: A single institution’s experience. Transplant Proc 2010; 42: 644-6.
[16]
Bispo M, Marcelino P, Marques HP, et al. Domino versus deceased donor liver transplantation: Association with early graft function and perioperative bleeding. Liver Transpl 2011; 17: 270-8.
[17]
Azoulay D, Samuel D, Castaing D, et al. Domino liver transplants for metabolic disorders: Experience with familial amyloidotic polyneuropathy. J Am Coll Surg 1999; 189: 584-93.
[18]
Schmidt HH, Nashan B, Pröpsting MJ, et al. Familial Amyloidotic Polyneuropathy: Domino liver transplantation. J Hepatol 1999; 30: 293-8.
[19]
Bittencourt PL, Couto CA, Leitão RMC, et al. No evidence of de novo amyloidosis in recipients of domino liver transplantation: 12 to 40 (mean 24) month follow-up. Amyloid 2002; 9: 194-6.
[20]
Furtado AJ. Domino liver transplantation using FAP grafts. HUC experience--hopes and realities. Amyloid 2003; 10(Suppl. 1): 84-7.
[21]
Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med 2005; 352: 2356.
[22]
Barreiros A-P, Post F, Hoppe-Lotichius M, et al. Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: A single-center experience. Liver Transpl 2010; 16: 314-23.
[23]
Abdelfatah MM, Hayman SR, Gertz MA. Domino liver transplantation as a cause of acquired familial amyloid polyneuropathy. Amyloid 2014; 21: 136-7.
[24]
Misumi Y, Oshima T, Ueda M, et al. Occurrence factors and clinical picture of iatrogenic transthyretin amyloidosis after domino liver transplantation Amyloid 2017; 24(sup1). : 123-4.
[25]
Mnatsakanova D, Živković SA. Iatrogenic amyloid polyneuropathy after domino liver transplantation. World J Hepatol 2017; 9: 126-30.
[26]
Adams D, Lacroix C, Antonini T, et al. Symptomatic and proven de novo amyloid polyneuropathy in familial amyloid polyneuropathy domino liver recipients. Amyloid 2011; 18(Suppl. 1): 174-7.
[27]
Dixit N, Castano A, Farr MJ, et al. Rapidly progressive transthyretin-mediated amyloidosis in a domino liver transplant recipient of a Ser23Asn donor. J Clin Neuromuscul Dis 2016; 17: 142-5.
[28]
Misumi Y, Narita Y, Oshima T, et al. Recipient aging accelerates acquired transthyretin amyloidosis after domino liver transplantation. Liver Transpl 2016; 22: 656-64.
[29]
Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 2016; 23: 209-13.
[30]
Bourque PR, Shafi S, Jansen GH, McCurdy A, Warman Chardon J. Amyloid neuropathy following domino liver transplantation: Response to diflunisal. JAMA Neurol 2016; 73: 477-8.
[31]
Vieira H, Rodrigues C, Pereira L, et al. Liver retransplantation in patients with acquired familial amyloid polyneuropathy: A portuguese center experience. Transplant Proc 2015; 47: 1012-5.
[32]
Antonini TM, Lozeron P, Lacroix C, et al. Reversibility of acquired amyloid polyneuropathy after liver retransplantation. Am J Transplant 2013; 13: 2734-8.
[33]
Nunes F, Valente M, Pereira R, Amil M. Domino liver transplant: Influence on the number of donors and transplant coordination. Transplant Proc 2004; 36: 916-7.
[34]
Chuang DT. Maple syrup urine disease: It has come a long way. J Pediatr 1998; 132(3 Pt 2): S17-23.
[35]
Korein J, Sansaricq C, Kalmijn M, Honig J, Lange B. Maple syrup urine disease: Clinical, EEG, and plasma amino acid correlations with a theoretical mechanism of acute neurotoxicity. Int J Neurosci 1994; 79(1-2): 21-45.
[36]
Strauss KA, Mazariegos GV, Sindhi R, et al. Elective liver transplantation for the treatment of classical maple syrup urine disease. Am J Transplant 2006; 6: 557-64.
[37]
Barshop BA, Khanna A. Domino hepatic transplantation in maple syrup urine disease. N Engl J Med 2005; 353: 2410-1.
[38]
Khanna A, Hart M, Nyhan WL, et al. Domino liver transplantation in maple syrup urine disease. Liver Transpl 2006; 12: 876-82.
[39]
Mohan N, Karkra S, Rastogi A, Vohra V, Soin AS. Living donor liver transplantation in maple syrup urine disease - Case series and world’s youngest domino liver donor and recipient. Pediatr Transplant 2016; 20: 395-400.
[40]
Roda KMO, Vincenzi R, Fonseca EA, et al. Domino liver transplant in maple syrup urine disease. Transplantation 2019; 103(3): 536-43.
[41]
Bilheimer DW, Stone NJ, Grundy SM. Metabolic studies in familial hypercholesterolemia. J Clin Invest 1979; 64: 524-33.
[42]
Naoumova RP, Thompson GR, Soutar AK. Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol 2004; 15: 413-22.
[43]
Bilheimer DW, Goldstein JL, Grundy SM, Starzl TE, Brown MS. Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. N Engl J Med 1984; 311: 1658-64.
[44]
Popescu I, Simionescu M, Tulbure D, et al. Homozygous familial hypercholesterolemia: Specific indication for domino liver transplantation. Transplantation 2003; 76(9): 1345-50.
[45]
Liu C, Loong C-C, Hsia C-Y, et al. Venoplasty of hepatic venous outflow with a venous patch in domino liver transplantation. Liver Transpl 2008; 14: 1378-9.
[46]
Liu C, Niu D-M, Loong C-C, et al. Domino liver graft from a patient with homozygous familial hypercholesterolemia. Pediatr Transplant 2010; 14: E30-3.
[47]
Popescu I, Habib N, Dima S, et al. Domino liver transplantation using a graft from a donor with familial hypercholesterolemia: Seven-yr follow-up. Clin Transplant 2009; 23: 565-70.
[48]
Golbus JR, Farhat L, Fontana RJ, Rubenfire M. Rapidly progressive atherosclerosis after domino liver transplantation from a teenage donor with homozygous familial hypercholesterolemia. J Clin Lipidol 2017; 11: 1284-8.
[49]
Danpure CJ. Molecular and clinical heterogeneity in primary hyperoxaluria type 1. Am J Kidney Dis 1991; 17: 366-9.
[50]
Danpure CJ, Smith LH. The primary hyperoxalurias. Kidney stones Med Surg Manag 1996; 1996 : 859 -1 .
[51]
Jamieson NV, Jamieson KA. Primary hyperoxaluria Type 1: Gene therapy by liver transplantation. Transplantation 2009; 87: 1273-4.
[52]
Donckier V, El Nakadi I, Closset J, et al. Domino hepatic transplantation using the liver from a patient with primary hyperoxaluria. Transplantation 2001; 71: 1346-8.
[53]
Saner FH, Treckmann J, Pratschke J, et al. Early renal failure after domino liver transplantation using organs from donors with primary hyperoxaluria type 1. Transplantation 2010; 90: 782-5.
[54]
Casas-Melley AT, Thomas PG, Krueger LJ, et al. Domino as a bridge to definitive liver transplantation in a neonate. Pediatr Transplant 2002; 6: 249-54.
[55]
Chapman KA, Summar ML. Propionic acidemia consensus conference summary. Mol Genet Metab 2012; 105: 3-4.
[56]
Barshes NR, Vanatta JM, Patel AJ, et al. Evaluation and management of patients with propionic acidemia undergoing liver transplantation: A comprehensive review. Pediatr Transplant 2006; 10: 773-81.
[57]
Vara R, Turner C, Mundy H, et al. Liver transplantation for propionic acidemia in children. Liver Transpl 2011; 17: 661-7.
[58]
Moguilevitch M, Delphin E. Domino liver transplantation from a child with propionic acidemia to a child with idiopathic fulminant hepatic failure. Case Rep Transplant 2018; 2018: 1-3.
[59]
Govil S, Shanmugam NP, Reddy MS, Narasimhan G, Rela M. A metabolic chimera: Two defective genotypes make a normal phenotype. Liver Transpl 2015; 21: 1453-4.
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Related Books
Drug Addiction Mechanisms in the Brain
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Biotechnology and Drug Development for Targeting Human Diseases
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Enzymatic Targets for Drug Discovery Against Alzheimer's Disease
Medicinal Plants, Phytomedicines and Traditional Herbal Remedies for Drug Discovery and Development against COVID-19
Advanced Pharmacy
Plant-derived Hepatoprotective Drugs
Brain Tumor Targeting Drug Delivery Systems: Advanced Nanoscience for Theranostics Applications
Article Metrics
49
4